ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In 2001, the US Food and Drug Administration (FDA) approved the first TKI imatinib, which targets the breakpoint cluster region protein- Abelson murine leukemia viral oncogene homolog (BCR-ABL) oncogene, and brought a revolutionary success to the treatment of chronic myeloid leukemia (CML) (34).